Viome Acquires Circulate Health to Enhance Precision Nutrition and Therapy
Viome Life Sciences has recently announced its acquisition of Circulate Health, a move that aims to integrate Viome’s advanced molecular diagnostics and precision nutrition platform with Circulate’s innovative therapeutic plasma exchange (TPE) services. This strategic acquisition not only enhances Viome’s capabilities in the realm of precision health but also broadens its access to Circulate’s extensive network of clinical partners, now exceeding 200 clinics across the nation. The financial details of the acquisition have not been disclosed.
Circulate Health has been at the forefront of expanding therapeutic plasma exchange beyond traditional hospital settings, focusing on clinical protocols that target healthspan and chronic disease management. Notably, Circulate's approach includes efforts to address the presence of circulating microplastics in the body, a growing concern in public health.
Dr. Brad Younggren, co-founder and CEO of Circulate Health, will transition to Viome as the president of Viome PRO, the newly established clinical division of the company. Viome’s acquisition of Circulate aligns with its broader strategy to connect diagnostic insights with personalized health interventions, enabling the measurement of health outcomes over time.
Therapeutic plasma exchange has been utilized in hospitals for over fifty years, primarily for treating certain autoimmune and neurological conditions. Circulate has been exploring its applications within the field of longevity medicine, suggesting a novel approach to enhancing health and potentially extending lifespan.
In support of its innovative TPE procedure, Circulate referenced a study from 2026 that indicated a reduction in circulating microplastic levels among patients with elevated baseline levels following treatment. Additionally, a 2025 study reported an average decrease of 2.6 years in biological age across various molecular biomarkers after undergoing Circulate's protocol.
Viome employs RNA sequencing technology licensed from Los Alamos National Laboratory, coupled with artificial intelligence, to develop non-invasive tests for early detection of cancers and chronic diseases. The company’s philosophy emphasizes that declining health is not an inevitable process. Instead, Viome advocates for a future of medicine focused on measurable health improvements rather than merely treating diseases.
Dr. Younggren expressed enthusiasm about the merger, stating, "Longevity medicine has reached an inflection point. We can measure more about human biology than ever before, and the field now has real, proven ways to act on those insights. The integration of precision plasma exchange with Viome’s molecular platform offers clinicians a more credible approach to practicing longevity medicine, marking a significant advancement for patient care."




